Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been provided clearance by Portuguese, Swedish, and British regulatory authorities to begin with clinical testing cialis acheter http://letadalafil.net . The trial will start enrolling individuals in a blinded shortly, randomized, placebo-controlled, multicenter Phase I study. ALN-TTR01 is a systemically shipped RNAi therapeutic being created for the treatment of transthyretin -mediated amyloidosis , including familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy . Pre-clinical research in a mouse transgenic model have shown that treatment with ALN-TTR01 results in regression of pre-existing pathogenic TTR deposits in peripheral tissues including dorsal root ganglia, sciatic nerve, abdomen, and intestines.

tadalafil online

Copyright 2009 Advisory Board Business and Kaiser Family Base. All rights reserved.. Also in global wellness news: Global Fund; MDGs, women; polio eradication Radio Australia Interviews Global Fund Executive Director Radio Australia examines the Global Fund to Combat Helps, Tuberculosis and Malaria’s press for more funding from Australia and China. Global Fund Executive Director ‘Michel Kazatchkine is currently touring the world’s capitals searching for renewed authorities pledges to build on an already impressive record and as well as seeking to Australia to do more, he’s hoping shortly to obtain China to become not just recipient, but donor.’ The show features an interview with Kazatchkine . U.N. Event TARGETS Women’s Rights, Mon to mark International Corporate Philanthropy Day time MDG Target At an event, the U.N.